A meaningful exploration of ofatumumab in refractory NMOSD: a case report

作者：Yibo Zhan, Min Zhao, Xiaojun Li, Huiying Ouyang, Chenghao Du, Guixian Chen, Zhenzhen Lou, Haoxuan Chen, Yuanqi Zhao, Haoyou Xu · 发表于：Frontiers in Immunology · 年份：2023 · DOI：10.3389/fimmu.2023.1208017 · 被引用次数：7 · 研究领域：Multiple Sclerosis Research Studies、Peripheral Neuropathies and Disorders、Systemic Lupus Erythematosus Research

Objective: To report the case of a patient with refractory neuromyelitis optica spectrum disorder (NMOSD), who, despite showing poor response or intolerance to multiple immunosuppressants, was successfully treated with Ofatumumab. Case presentation: A 42-year-old female was diagnosed with NMOSD in the first episode of the disease. Despite treatment with intravenous methylprednisolone, immunoglobulin, rituximab and immunoadsorption, together with oral steroids, azathioprine, mycophenolate mofetil and tacrolimus, she underwent various adverse events, such as abnormal liver function, repeated infections, fever, rashes, hemorrhagic shock, etc., and experienced five relapses over the ensuing four years. Finally, clinicians decided to initiate Ofatumumab to control the disease. The patient received 9 doses of Ofatumumab over the next 10 months at customized intervals. Her symptoms were stable and there was no recurrence or any adverse events. Conclusion: Ofatumumab might serve as an effective and safe alternative for NMOSD patients who are resistant to other current immunotherapies.